Neumora Therapeutics, Inc., was originally incorporated in Delaware in November 2019. The company is a clinical-stage biopharmaceutical company that aims to address the greatest medical challenge of its generation by proposing the next generation of new brain penetration chemotherapy to provide patients with better treatment outcomes and quality of life. The company's therapeutic pipeline currently includes projects for new mechanisms of action for a variety of underserved endemic diseases.
